200 related articles for article (PubMed ID: 10599303)
21. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
22. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.
Miller E; Andrews NJ; Waight PA; Slack MP; George RC
Lancet Infect Dis; 2011 Oct; 11(10):760-8. PubMed ID: 21621466
[TBL] [Abstract][Full Text] [Related]
23. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
24. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs.
Weycker D; Richardson E; Oster G
Am J Manag Care; 2000 Jul; 6(10 Suppl):S526-35. PubMed ID: 11183904
[TBL] [Abstract][Full Text] [Related]
25. Prevenar experience.
Arguedas A; Soley C; Abdelnour A
Vaccine; 2011 Sep; 29 Suppl 3():C26-34. PubMed ID: 21896350
[TBL] [Abstract][Full Text] [Related]
26. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
Fedson DS
Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
[TBL] [Abstract][Full Text] [Related]
27. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies.
Sniadack DH; Schwartz B; Lipman H; Bogaerts J; Butler JC; Dagan R; Echaniz-Aviles G; Lloyd-Evans N; Fenoll A; Girgis NI
Pediatr Infect Dis J; 1995 Jun; 14(6):503-10. PubMed ID: 7667055
[TBL] [Abstract][Full Text] [Related]
28. The pharmacoeconomics of pneumococcal conjugate vaccines in Latin America.
Giglio N; Micone P; Gentile A
Vaccine; 2011 Sep; 29 Suppl 3():C35-42. PubMed ID: 21896351
[TBL] [Abstract][Full Text] [Related]
29. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
30. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
Zangeneh TT; Baracco G; Al-Tawfiq JA
Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
[TBL] [Abstract][Full Text] [Related]
31. Prevention of respiratory infections in adults. Influenza and pneumococcal vaccines.
Fiebach N; Beckett W
Arch Intern Med; 1994 Nov; 154(22):2545-57. PubMed ID: 7979851
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis.
Pavia M; Bianco A; Nobile CG; Marinelli P; Angelillo IF
Pediatrics; 2009 Jun; 123(6):e1103-10. PubMed ID: 19482744
[TBL] [Abstract][Full Text] [Related]
33. Capsular serotypes and antimicrobial susceptibilities of Streptococcus pneumoniae causing invasive pneumococcal disease from 2009-2012 with an emphasis on serotype 19A in bacteraemic pneumonia and empyema and β-lactam resistance.
Lee MR; Chen CM; Chuang TY; Huang YT; Hsueh PR
Int J Antimicrob Agents; 2013 Nov; 42(5):395-402. PubMed ID: 24071028
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
[TBL] [Abstract][Full Text] [Related]
35. Pneumococcal vaccine: a second look. Solution for SC or IM injection: pneumococcal vaccine.
Prescrire Int; 1998 Feb; 7(33):16-8. PubMed ID: 10183394
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
37. Pneumococcal vaccine in the United States. A critical analysis.
Hirschmann JV; Lipsky BA
JAMA; 1981 Sep; 246(13):1428-32. PubMed ID: 7265447
[TBL] [Abstract][Full Text] [Related]
38. Clinical effectiveness of pneumococcal vaccine. Meta-analysis.
Hutchison BG; Oxman AD; Shannon HS; Lloyd S; Altmayer CA; Thomas K
Can Fam Physician; 1999 Oct; 45():2381-93. PubMed ID: 10540698
[TBL] [Abstract][Full Text] [Related]
39. [The elderly should be vaccinated against pneumococci].
Ortqvist A; Hedlund J; Kalin M
Lakartidningen; 1999 Mar; 96(11):1305-8. PubMed ID: 10194909
[TBL] [Abstract][Full Text] [Related]
40. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
Mokaddas E; Albert MJ
Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
